Human Anti-SARS-CoV-2 Spike-RBD Imdevimab (REGN10987) Neutralizing mAb

Synonyms:

Spike glycoprotein, S glycoprotein receptor binding domain, S-RBD, REGN10987, Imdevimab

Species:

SARS-CoV-2

Cat. No.:

CPC512B pdf (datasheet)

Quantity/Size:

100 µg

Concentration:

1.0 mg/ml, lot specific

Description:

New catalog number DVV00305

Recombinant Human anti-SARS-CoV-2 Spike Protein Receptor Binding Domain, Casirivimab Clone REGN10987, is expressed in XtenCHO. REGN10987was originally isolated from a humanized mouse immunized with SARS-CoV-2 Spike RBD protein. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). The structural proteins of SARS-CoV-2 include the envelope protein (E), spike or surface glycoprotein (S), membrane protein (M) and the nucleocapsid protein (N). The spike glycoprotein is found on the outside of the virus particle and gives coronavirus viruses their crown-like appearance. Surface glycoprotein is an important target for vaccine development, antibody therapies and diagnostic antigen-based tests.

Uniprot Name:

Spike glycoprotein

Uniprot ID:

P0DTC2

Data PDF:

CPC512

Purity:

> 95% by reducing and non-reducing SDS-PAGE

Specificity:

Recognizes SARS-CoV-2 Spike-RBD protein

Immunogen:

Recombinant SARS-CoV-2 Spike-RBD protein

Isotype:

IgG

Clone:

REGN10987 (Imdevimab)

Formulation:

Sterile-filtered PBS, pH 7.5 preservative free.

Purification:

Protein A affinity chromatography

Application:

ELISA, FS , Neutralizing , WB

Storage/Stability:

Stable at 2-8°C for 1 week or for up to 1 year at -20°C to -80°C. It is recommended to prepare single-use aliquots of undiluted product and store -20°C to -80°C.